Rising rates of depression amid the coronavirus pandemic underscore the need for innovations in mental health care, like psychedelics, according to George Goldsmith, CEO, chairman, and co‑founder of mental health company COMPASS Pathways.
"About 322 million people suffer from depression around the world — and that was before this current pandemic — but about 100 million of those just aren't helped by current treatment," Goldsmith told Cheddar. "So we really focused a lot on, 'how do we bring innovation to patients?'"
COMPASS Pathways is a United Kingdom-based biotech startup, researching a synthetic form of the psychedelic compound, psilocybin, for treatment resistant depression. Its drug, called COMP360, received "breakthrough therapy designation" from the U.S. Food and Drug Administration in 2018, meaning there was evidence it could substantially improve treatment over existing therapies and could move more quickly through drug development.
"We're working closely with regulators in every country that we're working with to develop clinical trials, and if those clinical trials are successful, then those medicines will be made available to patients," Goldsmith said.
The time is right for innovations in mental health care. Stressors related to the coronavirus pandemic may have tripled rates of depression across the U.S., according to a survey published in JAMA Network Open in early September. Some 27.8 percent of adults reported experiencing depression symptoms amid the pandemic, compared with 8.5 percent previously, according to the survey results. And the burden fell disproportionately on people who had limited financial or social resources.
"A single experience, a single dose of psilocybin for many people, can create an immediate and sustained benefit for people suffering with depression. And that really intrigued us," Goldsmith said.
COMPASS Pathways debuted on Nasdaq in September in a $146.6 million upsized initial public offering. It's move kicked off a flurry of interest from other psychedelic health and wellness companies looking to go public or uplist for similar access to liquidity and investors. Goldsmith said that for COMPASS Pathways, the move was motivated by expenses associated with the research the company is doing in nine countries.
"We're committed to really addressing mental health care at scale, and capital, shareholder capital, really helps with that," Goldsmith said.
U.S. sports betting is booming as NFL and college football fuel massive activity. BetMGM CEO Adam Greenblatt breaks down trends, growth, and what’s next.
President Donald Trump says a deal struck by Netflix last week to buy Warner Bros. Discovery “could be a problem” because of the size of the combined market share. The Republican president says he will be involved in the decision about whether federal regulators should approve the deal. Trump commented Sunday when he was asked about the deal as he walked the red carpet at the Kennedy Center Honors. The $72 billion deal would bring together two of the biggest players in television and film and potentially reshape the entertainment industry.
Disney's changes to a program for disabled visitors are facing challenges in federal court and through a shareholder proposal. The Disability Access Service program, which allows disabled visitors to skip long lines, was overhauled last year. Disney now mostly limits the program to those with developmental disabilities like autism who have difficulty waiting in lines. The changes have sparked criticism from some disability advocates. A shareholder proposal submitted by disability advocates calls for an independent review of Disney's disability policies. Disney plans to block this proposal, claiming it's misleading. It's the latest struggle by Disney to accommodate disabled visitors while stopping past abuses by some theme park guests.
With a merger this big, creators, studios, and theaters all face uncertain futures. Here’s what experts are worried about and what good could come from it.
With disengagement rising and hybrid work shifting, 'Everybody Matters' author Bob Chapman explains why treating people well could define the future of work.
We sat down with Ali Furman, U.S. Consumer Markets Industry Leader at consulting firm PwC to ask what trends she garnered from the initial data this year.
Seth Schachner breaks down Zootopia 2’s record-smashing debut, holiday box office trends, early 2026 Oscar contenders, and what’s next for Netflix and WBD.
